Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS Rating: 5.03, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.03 new
Vol. 3, Issue 8 (2014)

Polymorphic variants of ADRB2, NR3C1, MDR1 genes as possible predictors of efficacy of combined therapy laba + ICS in patients with chronic obstructive pulmonary disease

Author(s):
N.G. Gorovenko, G.Y. Stupnytska, S.V. Podolskaya
Abstract:
The aim of the study was to analyze possible associations efficacy in combined therapy LABA + ICS in patients with chronic obstructive pulmonary disease (COPD) with genotypes for genes ADRB2 (A46G and C79G), NR3C1(C646G), MDR1(C3435T). These findings demonstrate the high efficiency of combined therapy LABA + ICS in patients with CC and CG genotypes for gene ADRB2 (C79G) and an increased risk of negative response on treatment in patients with genotype GG for gene ADRB2 (C79G), which indicates the possibility of using complex clinical data, results of instrumental, laboratory testing and genetic testing for predicting the effectiveness of treatment.
Pages: 10-14  |  639 Views  7 Downloads
How to cite this article:
N.G. Gorovenko, G.Y. Stupnytska, S.V. Podolskaya. Polymorphic variants of ADRB2, NR3C1, MDR1 genes as possible predictors of efficacy of combined therapy laba + ICS in patients with chronic obstructive pulmonary disease. 2014; 3(8): 10-14.
Journals List Click Here Research Journals Research Journals
Call for book chapter